Mounjaro Weight Loss Services in Newport Beach, CA
Mounjaro (tirzepatide) entered the pharmaceutical market as a diabetes medication — and almost immediately became one of the most discussed drugs in all of medicine, because its weight outcomes in diabetic patients rewrote what anyone thought was pharmacologically possible. For patients in Newport Beach, CA, Adonis Saremi, MD delivers physician-supervised Mounjaro therapy through a program that pairs this medication’s extraordinary potency with the clinical oversight it demands.
What Is Mounjaro — and How Does It Compare?
Mounjaro (tirzepatide 2.5 to 15 mg, once-weekly subcutaneous injection) is FDA-approved for type 2 diabetes management. As a dual GIP and GLP-1 receptor agonist, it simultaneously engages both incretin pathways — producing complementary metabolic effects that neither mechanism achieves as effectively on its own. In the SURPASS-2 trial, tirzepatide delivered HbA1c reductions up to 2.4 percentage points and 12.4 kg more weight loss than semaglutide 1 mg in a head-to-head comparison.
How Tirzepatide’s Dual Mechanism Works
- GLP-1 receptor activation — appetite suppression, delayed gastric emptying, improved insulin secretion
- GIP receptor activation — enhanced insulin response, additional appetite reduction, favorable fat tissue regulation
- Synergistic receptor engagement — effects exceed what either mechanism achieves individually
- Superior beta-cell support — stronger stimulation of insulin-producing cells than GLP-1 monotherapy
- Broad metabolic normalization — simultaneous improvements in glucose, lipids, and blood pressure
Who Benefits Most from Mounjaro in Newport Beach?
- Adults in Newport Beach with type 2 diabetes who need superior glycemic control and clinically meaningful weight loss from a single weekly injection
- Patients on a GLP-1 monotherapy who have plateaued and want a specialist’s evaluation of whether dual agonism is the appropriate next step
- Individuals with significant insulin resistance, metabolic syndrome, or complex cardiometabolic profiles who need a medication with broad reach
- Those who previously tried semaglutide with suboptimal results and want a comparison-informed clinical upgrade
- Patients in Newport Beach who want their Mounjaro program actively supervised — regular dose management, lab monitoring, and a physician who adjusts as the data evolves
Our Mounjaro Program in Newport Beach
Candidacy Evaluation
Prescribing Mounjaro begins with a complete clinical review — HbA1c, fasting glucose, kidney function, liver enzymes, lipids, BMI, and full comorbidity and medication history. Contraindications including thyroid cancer history and MEN 2 syndrome are addressed before therapy is initiated.
Titration Protocol
Mounjaro is introduced at 2.5 mg weekly and titrated at four-week intervals up to 15 mg. Dr. Adonis Saremi manages escalation pace based on your clinical response — never accelerating beyond what your body is ready to handle.
Continuous Lab Monitoring
HbA1c, kidney function, lipid panels, and liver markers are tracked throughout your Newport Beach program — giving Dr. Adonis Saremi the data to optimize protocol and catch emerging concerns early.
Why Choose Dr. Adonis Saremi, MD for Mounjaro in Newport Beach?
The Expertise to Use It Well
Dr. Adonis Saremi’s dual certification in Obesity Medicine and Internal Medicine means your tirzepatide program is managed with the metabolic and cardiovascular expertise this class of medication demands.
Explore Mounjaro weight management in Newport Beach. Call (619) 736-1748 or book your consultation online today.
Frequently Asked Questions
Can Mounjaro be used for weight loss if I do not have diabetes?
Mounjaro is FDA-approved for type 2 diabetes. For weight loss in non-diabetic patients, the same compound is available as Zepbound — FDA-approved specifically for chronic weight management. Your physician will identify the most appropriate pathway.
How is Mounjaro different from Ozempic?
Mounjaro activates both GLP-1 and GIP receptors; Ozempic activates GLP-1 only. Head-to-head data (SURPASS-2) shows tirzepatide produces greater HbA1c reduction and more weight loss than semaglutide 1 mg — establishing dual agonism as the more potent approach for most patients.